CTOs on the Move

Delcath

www.delcath.com

 
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company`s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.delcath.com
  • 1633 Broadway 22nd Floor, Suite C
    New York, NY USA 10019
  • Phone: 212.489.2100

Executives

Name Title Contact Details

Funding

Delcath raised $35M on 06/07/2016
Delcath raised $20M on 07/23/2019
Delcath raised $22.2M on 12/11/2020

Similar Companies

Creyon Bio

Creyon Bio is a company that is reinventing drug development from the ground up to make safe, effective oligonucleotide based medicines possible—on demand.

Medico Labs Inc

Medico Labs Inc is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rib-X Pharmaceuticals

Rib-X Pharmaceuticals, Inc. is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HTL-STREFA S.A.

QLT Inc

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases. QLT`s head office is based in Vancouver, Canada and the company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT).